Among the transaction's projects, the product involved in the collaboration and licensing between CSPC Megalith Biopharmaceutical and AstraZeneca primarily relates to an innovative peptide molecule along with related technologies and products, currently in the preclinical research stage. It aims to provide a longer-lasting treatment solution for individuals with obesity and weight-related concerns. Furthermore, there exists the possibility for CSPC Megalith Biopharmaceutical and AstraZeneca to engage in strategic collaboration on other related projects in the fields of innovative peptide molecule discovery and long-acting delivery product development.

C-CAR031 is an autologous, Glypican-3 (GPC3)-targeting chimeric antigen receptor T-cell (CAR-T) therapy. Based on AstraZeneca's novel GPC3-targeting CAR-T candidate (AZD5851), it is designed using AstraZeneca's dominant negative transforming growth factor-beta receptor II (dnTGFβRII) armoring platform and is manufactured by AbelZeta in China. It is currently being investigated for the treatment of hepatocellular carcinoma (HCC) and other solid tumors.

Over the past seven years, AstraZeneca has consistently aligned with the "Healthy China 2030" goals, bringing a total of 18 "CIIE-born" products covering respiratory, renal, digestive, rare diseases, autoimmune conditions, and multiple cancer types, providing patients with more treatment options.

The recent landmark deal provides a tangible blueprint for the next phase of China's innovative drugs going global.

At the 14th China Rare Disease Summit 2025, Dr. Gianluca Pirozzi addressed the theme of "Accelerating Rare Disease R&D Innovation," sharing insights on the current industry landscape, existing challenges, and AstraZeneca's practical initiatives.

On September 19, 2025, AstraZeneca registered the Phase III clinical trial of the small-molecule PCSK9 inhibitor AZD0780 film-coated tablets on the website of China Drug Trials. This trial is intended for adults with confirmed cardiovascular disease (CVD) or adults at high risk of CVD events to reduce cardiovascular risk.

On September 17, the China's Center for Drug Evaluation (CDE) website disclosed that AstraZeneca (AZN.US) has submitted an application in China for a new indication of Budesonide/Glycopyrronium/Formoterol Inhalation Aerosol (Breztri®). Based on clinical trial progress, the proposed indication is speculated to be asthma.

AstraZeneca's application for the new indication of benralizumab has been accepted in China for the treatment of hypereosinophilic syndrome. The drug has already been approved for multiple indications in many regions worldwide, with sales continuing to grow. AstraZeneca is also developing the drug for other indications, and it is expected to see sustained growth in the future.